Glaxo's RSV Vaccine Snub: A Missed Opportunity for the NHS

UK pharmaceutical company Glaxo's RSV vaccine has been overlooked by the NHS in favor of a cheaper alternative from Pfizer, highlighting a broader issue of the UK's commitment to preventative medicine and domestic pharmaceutical innovation. The decision comes despite the GSK vaccine being 10% more efficacious and having regulatory approvals on both sides of the Atlantic. This snub is a missed opportunity for the NHS to prioritize the best treatment options for vulnerable populations, including mothers and the elderly.

Key Takeaways:

• The NHS has chosen Pfizer's RSV vaccine over Glaxo's, despite the latter being 10% more efficacious.
• Glaxo's RSV vaccine has regulatory approvals on both sides of the Atlantic and already supplies two-thirds of its protection to the US market.
• The decision highlights the need for the NHS to prioritize preventative medicine and domestic pharmaceutical innovation.
• UK pharmaceutical company Glaxo is a major advocate for UK pharmaceuticals and has made a strong case for preventative medicine in the NHS.
• The GSK vaccine's higher efficacy and existing approvals make it a more attractive option for protecting vulnerable populations.

Statistics:

• 10%: The efficacy difference between Glaxo's RSV vaccine and Pfizer's alternative.
• 2/3: The proportion of GSK's RSV protection supplied to the US market.
• 10%: The proportion of the US RSV market controlled by Glaxo.
• Regulatory approvals: Glaxo's RSV vaccine has approvals on both sides of the Atlantic, including in the US and Europe.

Sources:

• [2] The text does not provide a specific source reference, but the information appears to be based on publicly available information about Glaxo and Pfizer's RSV vaccines.